Zevra Therapeutics, Inc. ZVRA
11.04
(0.22)
(1.95%)
as of 25 Sep
- Market cap
- $668.7M
- P/E
- 11.6×
Follow ZVRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
28.11% | 79.85% | 94.80% | 34.33% | |
| 12.36% | 33.52% | 51.85% | 20.57% | ||
ROIC |
0.00% | (153.83%) | (65.48%) | 0.00% | |
Return on Tangible Assets |
14.30% | 42.12% | 63.81% | 28.27% | |
Average Days of Receivables |
72.84 | 79.73 | 65.96 | 60.33 | |
Free Cash Flow per Share |
(0.42) | (0.04) | 0.21 | 0.56 | |
Free Cash Flow |
(23.71) | (1.98) | 12.49 | 33.07 | |
Capital Expenditures |
(0.35) | (0.39) | (0.28) | (0.33) | |
Piotroski F-Score |
6.00 | 6.00 | 7.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
(5.93%) | (0.39%) | 3.14% | 7.60% | |
Accounts Receivable Turnover |
6.85 | 6.31 | 7.05 | 6.68 | |
Accounts Payable Turnover |
0.92 | 0.89 | 1.15 | 0.41 | |
Inventory Turnover |
0.00 | 8.89 | 7.00 | 3.47 | |
Average Days of Payables |
247.51 | 256.84 | 250.45 | 824.62 | |
Days of Inventory on Hand |
30.56 | 38.53 | 49.50 | 144.64 | |
Tax Rate |
(0.34) | (0.04) | (0.07) | (0.16) | |
Research and Development Expense of Revenue |
21.89% | 11.97% | 11.35% | 10.97% | |
Selling, General and Administrative Expense of Revenue |
86.96% | 72.90% | 64.48% | 54.85% | |
Share Based Compensation of Revenue |
14.83% | 11.94% | 10.32% | 9.65% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.82) | (0.02) | 0.11 | 0.58 | |
Depreciation/Fixed assets |
124.77 | 121.96 | 134.97 | (2.81) | |
Capex/Depreciation |
(0.01) | (0.01) | 0.00 | 0.18 | |
Revenue per Share |
1.51 | 1.92 | 2.09 | 2.30 | |
Operating CF per Share |
(0.42) | (0.03) | 0.22 | 0.56 | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
33.80% | 72.87% | 95.68% | 42.25% |
Columns are period end dates